|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400089601 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-11 16:12:51 |
|
注册时间: Date of Registration: |
2024-09-11 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
IVF周期中,新鲜胚胎移植和全胚冷冻策略对薄型子宫内膜患者活产结局的影响:一项多中心回顾性队列研究 |
|
Public title: |
Comparision of fresh embryo transfer and freeze-all strategy on live birth outcomes in patients with thin endometrium in IVF cycles: a multicentre retrospective cohort study |
|
注册题目简写: |
薄型子宫内膜患者,鲜胚移植还是全胚冷冻 |
|
English Acronym: |
Fresh ET or freeze-all for TE women? |
|
研究课题的正式科学名称: |
IVF周期中,新鲜胚胎移植和全胚冷冻策略对薄型子宫内膜患者活产结局的影响:一项多中心回顾性队列研究 |
|
Scientific title: |
Comparision of fresh embryo transfer and freeze-all strategy on live birth outcomes in patients with thin endometrium in IVF cycles: a multicentre retrospective cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
韩乔松 |
研究负责人: |
孙振高 |
|
Applicant: |
Qiaosong Han |
Study leader: |
Zhengao Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 156 6266 8561 |
研究负责人电话: Study leader's telephone: |
+86 137 0893 8621 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hqs199901@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
sunzhengao77@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东中医药大学附属医院,文化东路42号,山东济南 |
研究负责人通讯地址: |
山东中医药大学附属医院,文化东路42号,山东济南 |
|
Applicant address: |
Affiliated Hospital of Shandong University of Chinese medicine, NO.42 wenhua West Rd, Jinan, Shandong, China |
Study leader's address: |
Affiliated Hospital of Shandong University of Chinese medicine, NO.42 wenhua West Rd, Jinan, Shandong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
250011 |
研究负责人邮政编码: Study leader's postcode: |
250011 |
|
申请人所在单位: |
山东中医药大学 |
||
|
Applicant's institution: |
Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
山东中医药大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)伦审第(090)号-KY |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东中医药大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-15 00:00:00 |
||
|
伦理委员会联系人: |
袁杰 |
||
|
Contact Name of the ethic committee: |
Jie Yuan |
||
|
伦理委员会联系地址: |
山东省济南市经十路16369号 |
||
|
Contact Address of the ethic committee: |
No.16369, Jingshi Road, Jinan City, Shandong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 6861 6733 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东中医药大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市文化西路42号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 42, West Culture Road, Jinan, Shandong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自拟课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financed |
||||||||||||||||||||||
|
Target disease: |
Thin endometrium |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
主要目标 (1) 基于首次移植的分析: 评估子宫内膜薄的 IVF-ET 患者在首次胚胎移植周期中新鲜胚胎移植与全胚冷冻策略的活产率,从而提供证据支持或反驳将子宫内膜薄作为取消新鲜胚胎移植的标准。 (2) 基于时间-事件的分析: 通过计算累计活产率,评估新鲜胚胎移植和完全胚胎冷冻在促进单次试管婴儿治疗实现活产方面的功效,同时将实现活产的时间作为时间组成部分。 次要目标 (1) 评估接受新鲜胚胎移植或全部冷冻策略(后续的冻融胚胎移植)患者的其他妊娠结局和新生儿结局。 (2)评估在子宫内膜薄的人群中,子宫内膜厚度的变化是否会改变两种策略对首次移植活产率和累积活产率的影响。 (3) 评估新鲜胚胎移植和全部冷冻策略对子宫内膜薄妇女中不同亚群的影响差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objectives (1) First-transfer based analysis: To assess the incidence rate of live birth of fresh embryo transfer versus freeze-all strategy in the initial embryo transfer cycle for patients with a thin endometrium undergoing IVF-ET, thus providing evidence supporting or refuting the use of thin endometrium as a criterion for canceling fresh embryo transfers. (2) Time-to-event based analysis: To assess the efficacy of fresh embryo transfer and complete embryo freezing in facilitating the achievement of a live birth from a single IVF treatment by calculating the cumulative live birth rate, while considering the time to achieving live birth as a time component. Secondary objectives (1) To assess other pregnancy outcomes and neonatal outcomes of live births followed by the fresh embryo transfer or freeze-all strategy (frozen-thawed embryo transfer). (2) To assess whether variations in endometrial thickness alter the impact of two strategies on the live birth rate of the first transfer and cumulative live birth rate in a population with thin endometrium. (3) To assess the difference in the impact of fresh embryo transfer and freeze-all strategy in subgroups of women with a thin endometrium |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄 ≥ 20 周岁,且 ≤ 50周岁的女性; 2. 患者在 IVF 周期中的子宫内膜测量值满足薄型子宫内膜诊断,定义为: HCG扳机日经超声引导下 B 超测量的子宫内膜厚度 < 8 mm;子宫内膜厚度定义为通过超声测量的子宫中矢状面上从一个子宫内膜-子宫肌层界面到另一个界面的最大距离。通常而言,HCG 日的内膜厚度会作为决定是否对患者进行新鲜胚胎移植的决定因素之一,因此进行重复测量,并取平均值以避免误差; 3. 患者在 IVF 周期取卵后,又至少接受了一次后续的胚胎移植(新鲜移植或冻融胚胎移植)。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Women aged 20 to 50 years; 2.In an IVF cycle, if the endometrial thickness is diagnosed as thin, defined as an endometrial thickness < 8 mm measured via ultrasound on the HCG trigger day, the endometrial thickness is determined as the maximum distance from one interface between the endometrium and myometrium to the other in the sagittal plane of the uterus. The endometrial thickness on the HCG day is usually used to decide whether to proceed with a fresh embryo transfer. To minimize error, repeat measurements are taken and averaged; 3.The patient underwent at least one subsequent embryo transfer (either fresh or frozen) after egg retrieval in the IVF cycle. |
||||||||||||||||||||||
|
排除标准: |
研究排除了涉及以下内容的试管婴儿周期 : (1) 植入前基因检测或诊断; (2) 使用冷冻卵母细胞/精子; (3) 捐献卵细胞周期; (4) 体外成熟周期; (5) 存在其他取消鲜胚移植的明确指征的周期,包括: ①子宫腔、子宫附件存在异常,如子宫内膜结构障碍/息肉/腺肌病/内异症/输卵管积 水/宫腔憩室; ②扳机日孕酮已经升高(定义为>1.5 ng/ml); ③存在高卵巢过度刺激(OHSS)风险(定义为获卵数>=18 个) ④使用黄体期促排方案、高孕激素状态促排方案、克罗米芬促排方案的周期 (6) 没有取到卵母细胞、没有获得 2PN 子代细胞或在取卵后第三天没有可存活胚胎的周期也被排除在外。 |
||||||||||||||||||||||
|
Exclusion criteria: |
The study excluded IVF cycles involving: (1) Pre-implantation genetic testing or diagnosis; (2) The use of frozen oocytes/sperm; (3) Donor oocyte cycles; (4) In vitro maturation cycles; (5) There are cycles with clear indications for canceling fresh embryo transfer, including: ①Abnormalities in the uterine cavity or adnexa, such as endometrial structural disorders, polyps, adenomyosis, endometriosis, hydrosalpinx, or uterine diverticulum; ②Elevated progesterone on the trigger day (defined as > 1.5 ng/ml); ③Risk of severe ovarian hyperstimulation syndrome (OHSS) (defined as ≥ 18 oocytes retrieved); ④Cycles using luteal phase stimulation, high progesterone stimulation, or clomiphene stimulation protocols. (6) Cycles where no oocytes were retrieved, no 2PN zygotes were obtained, or no viable embryos were available on day three post-retrieval were also excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2016-01-01 00:00:00至 To 2024-10-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-01-06 00:00:00 至 To 2024-06-05 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
不适用 |
|
Blinding: |
Not applicable |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在期刊论文发表后,读者可联系通讯作者,在合理的要求下,本研究可以提供原始数据及用以数据分析的代码 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After publication of the journal paper, readers may contact the corresponding author and, upon reasonable request, the study can provide the raw data and the code used to analyze the data |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1. 数据处理和记录保存 患者的保密权至关重要。参与中心提供的所有电子数据库都将对患者信息进行匿名处理;因此,最终合并的数据库将不包含任何可识别的信息。任何研究人员都无法获得参与本研究的患者的完整身份信息。收集到的数据将仅用于本研究目的。 2. 数据保密和时限 数据将由参与中心的研究人员提供给山东中医药大学附属医院,并在那里进行整合和安全保护。韩乔松和郭子珍负责监督数据收集和合并数据库的建立,韩乔松和其他统计分析师负责数据清理和统计分析。 这项研究的时间安排--从接收所有数据、组装和清理数据库到统计分析和预期的初步结果--估计为六个月。截至试验注册前,数据库组装已经完成,数据清理正在进行,统计分析尚未开始。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. DATA HANDLING AND RECORD KEEPING The Patient’s right to confidentiality is paramount. All electronic databases provided by the participating centers will anonymize patient information; consequently, the final merged database will contain no identifiable information. No researcher will have access to the complete identity details of patients involved in this study. The collected data will be exclusively used for the purposes of this study. 2. DATA CONFIDENTIALITY AND TIMELINE Data will be supplied to the Affiliated Hospital of Shandong University of Traditional Chinese Medicine by investigators from the participating centers, where it will be consolidated and securely protected. Qiao-Song Han and Zi-Zhen Guo oversee the collection of data and the establishment of the merged database, while Qiao-Song Han and additional statistical analysts will conduct the data cleaning and statistical analyses. The timeline of the study—from the receipt of all data and the assembly and cleansing of the database to the statistical analyses and the anticipated initial results—is estimated at six months. Up to the trial registration, the database assembly is complete, data cleansing is underway, and statistical analysis has not yet commenced. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |